Department of Thyroid-breast-hernia Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Front Endocrinol (Lausanne). 2020 Apr 22;11:207. doi: 10.3389/fendo.2020.00207. eCollection 2020.
Anaplastic thyroid cancer is known to be the most lethal malignancy among endocrine tumors for its extremely limited survival rate after diagnosis. As a result of this poor survival prognosis, multimodal therapy is currently under investigation to address this global concern. In this reported case, the I seed implantation and vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor apatinib were co-applied to treat a 49-year-old woman with anaplastic thyroid cancer. After the patient began apatinib administration and underwent I seed implantation twice, the tumor size shrank successfully. After a follow-up of 13 months since the initial diagnosis of anaplastic thyroid cancer, the patient survived with a stable disease pathology. In conclusion, this study supports I seed implantation and apatinib as effective therapeutic alternatives for inoperable anaplastic thyroid cancer patients.
间变性甲状腺癌是内分泌肿瘤中最致命的恶性肿瘤，其诊断后的生存率极低。由于这种不良的生存预后，目前正在研究多模式治疗以解决这一全球性问题。在本报告的病例中，采用碘 125 粒子植入和血管内皮生长因子受体-2（VEGFR-2）抑制剂阿帕替尼联合治疗一名 49 岁的间变性甲状腺癌女性患者。患者开始阿帕替尼治疗并接受碘 125 粒子植入两次后，肿瘤大小成功缩小。从间变性甲状腺癌初始诊断开始随访 13 个月后，患者疾病稳定，存活下来。总之，本研究支持碘 125 粒子植入和阿帕替尼作为无法手术的间变性甲状腺癌患者的有效治疗选择。
